Clinical Trials
20 trialsNCT05143957 2026-06-01
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Ionis Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT06985147 2026-05-28
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Disc Medicine, Inc
Phase 2 Recruiting
NCT05558696 2026-05-07
IMG-7289-CTP-203
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 2 Completed
NCT07232290 2026-03-04
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2 Recruiting
NCT04182100 2025-09-15
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
PharmaEssentia Japan K.K.
Phase 2 Completed
NCT04629508 2025-09-02
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Phase 2 Completed
NCT04057040 2025-08-07
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Protagonist Therapeutics, Inc.
Phase 2 Completed
NCT05485948 2025-08-03
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
PharmaEssentia
Phase 2 Active not recruiting
NCT01761968 2025-04-30
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Italfarmaco
Phase 2 Active not recruiting
NCT04767802 2024-03-18
PACIFIC
Protagonist Therapeutics, Inc.
Phase 2 Completed
NCT02124746 2023-06-18
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Completed
NCT01981850 2022-01-05
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Hoffmann-La Roche
Phase 2 Completed
NCT03287245 2021-12-08
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Hoffmann-La Roche
Phase 2 Terminated
NCT03669965 2020-07-31
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Kartos Therapeutics, Inc.
Phase 2 Unknown
NCT01998828 2020-04-20
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT00606307 2019-12-03
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Italfarmaco
Phase 2 Completed
NCT00928707 2019-10-31
PV
Italfarmaco
Phase 2 Completed
NCT02125318 2017-02-27
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Galena Biopharma, Inc.
Phase 2 Completed
NCT01243073 2016-01-26
ET/PV
Geron Corporation
Phase 2 Completed
NCT00586651 2015-10-08
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed